Global Anti-Venom Market Size, Share, Trends and Forecast 2022-2030

Description

Antivenom, also known as antivenin, venom antiserum and antivenom immunoglobulin, is a medication made from antibodies which is used to treat certain venomous bites and stings.
Industry Insights

Due to the COVID-19 pandemic, the global Anti-Venom market size is estimated to be worth US$ 959.2 million in 2021 and is forecast to a readjusted size of US$ 1283.7 million by 2028 with a CAGR of 4.2% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Anti-Venom market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Anti-Venom landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.

CSL is the world leading manufacturer in global Anti-Venom market with the market share of 27%, in terms of revenue, followed by Merck, BTG, Pfizer, Haffkine Bio-Pharmaceutical, Rare Disease Therapeutics, Flynn Pharma, Vins Bioproducts, Bharat Serums and Vaccines, Serum Biotech and MicroPharm. These 11 companies accounted for 68% of the revenue market share in 2019. Asia-Pacific, Middle East and Africa are the largest consumption regions, occupied about 77% of market share, in terms of volume. The application of Anti-Venom in hospital and clinics take the main global shares. The polyvalent Anti-Venom takes more global revenue shares compared to the Monovalent Anti-Venom, which accounts for 67% in 2019.

This report focuses on Anti-Venom volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Anti-Venom market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China, Japan and India, etc.

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Post-covid-19 Outlook

The readers in the section will understand how the Anti-Venom market scenario changed across the globe during the pandemic and post-pandemic. The study is done keeping in view the changes in aspects such as sales, demand and supply chain. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.

Segmental Outlook

Key segments including type and application have been elaborated in this report. The consultants at QY Research have studied every segment and provided the market size using historical data. They have also talked about the growth opportunities that the segment may pose in the future. This study bestows sales and revenue data by type, and application during the historical period (2017-2022) and forecast period (2023-2028).

Segment by Type

Polyvalent Anti-Venom

Monovalent Anti-Venom

Segment by Application

Non-profit Institutions

Hospitals and Clinic

Regional Outlook

This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the revenue and sales data of each region and country for the period 2017-2028. This information derived through comprehensive research will help the reader to get familiar with the potential value of the investment in a particular region.

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Indonesia

Thailand

Malaysia

Philippines

Vietnam

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Scenario

In this section, the readers will gain an understanding of the key players competing. The experts at QY Research have studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2017-2022. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses. Some of the prominent players reviewed in the research report include:

CSL

Merck

BTG

Pfizer

Haffkine Bio-Pharmaceutical

Rare Disease Therapeutics

Flynn Pharma

Vins Bioproducts

Bharat Serums and Vaccines

Serum Biotech

MicroPharm

TABLE OF CONTENT

1 Anti-Venom Market Overview
1.1 Product Overview and Scope of Anti-Venom

1.2 Anti-Venom Segment by Type

1.2.1 Global Anti-Venom Sales Growth Rate Comparison by Type (2022-2028)

1.2.2 Polyvalent Anti-Venom

1.2.3 Monovalent Anti-Venom

1.3 Anti-Venom Segment by Application

1.3.1 Global Anti-Venom Sales Comparison by Application: (2022-2028)

1.3.2 Non-profit Institutions

1.3.3 Hospitals and Clinic

1.4 Global Anti-Venom Market Size Estimates and Forecasts

1.4.1 Global Anti-Venom Revenue 2017-2028

1.4.2 Global Anti-Venom Sales 2017-2028

1.4.3 Anti-Venom Market Size by Region: 2017 Versus 2021 Versus 2028

2 Anti-Venom Market Competition by Manufacturers

2.1 Global Anti-Venom Sales Market Share by Manufacturers (2017-2022)

2.2 Global Anti-Venom Revenue Market Share by Manufacturers (2017-2022)

2.3 Global Anti-Venom Average Price by Manufacturers (2017-2022)

2.4 Manufacturers Anti-Venom Manufacturing Sites, Area Served, Product Type

2.5 Anti-Venom Market Competitive Situation and Trends

2.5.1 Anti-Venom Market Concentration Rate

2.5.2 The Global Top 5 and Top 10 Largest Anti-Venom Players Market Share by Revenue

2.5.3 Global Anti-Venom Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Anti-Venom Retrospective Market Scenario by Region

3.1 Global Anti-Venom Retrospective Market Scenario in Sales by Region: 2017-2022

3.2 Global Anti-Venom Retrospective Market Scenario in Revenue by Region: 2017-2022

3.3 North America Anti-Venom Market Facts & Figures by Country

3.3.1 North America Anti-Venom Sales by Country

3.3.2 North America Anti-Venom Revenue by Country

3.3.3 U.S.

3.3.4 Canada

3.4 Europe Anti-Venom Market Facts & Figures by Country

3.4.1 Europe Anti-Venom Sales by Country

3.4.2 Europe Anti-Venom Revenue by Country

3.4.3 Germany

3.4.4 France

3.4.5 U.K.

3.4.6 Italy

3.4.7 Russia

3.5 Asia Pacific Anti-Venom Market Facts & Figures by Region

3.5.1 Asia Pacific Anti-Venom Sales by Region

3.5.2 Asia Pacific Anti-Venom Revenue by Region

3.5.3 China

3.5.4 Japan

3.5.5 South Korea

3.5.6 India

3.5.7 Australia

3.5.8 Taiwan

3.5.9 Indonesia

3.5.10 Thailand

3.5.11 Malaysia

3.5.12 Philippines

3.5.13 Vietnam

3.6 Latin America Anti-Venom Market Facts & Figures by Country

3.6.1 Latin America Anti-Venom Sales by Country

3.6.2 Latin America Anti-Venom Revenue by Country

3.6.3 Mexico

3.6.4 Brazil

3.6.5 Argentina

3.7 Middle East and Africa Anti-Venom Market Facts & Figures by Country

3.7.1 Middle East and Africa Anti-Venom Sales by Country

3.7.2 Middle East and Africa Anti-Venom Revenue by Country

3.7.3 Turkey

3.7.4 Saudi Arabia

3.7.5 UAE

4 Global Anti-Venom Historic Market Analysis by Type

4.1 Global Anti-Venom Sales Market Share by Type (2017-2022)

4.2 Global Anti-Venom Revenue Market Share by Type (2017-2022)

4.3 Global Anti-Venom Price by Type (2017-2022)

5 Global Anti-Venom Historic Market Analysis by Application

5.1 Global Anti-Venom Sales Market Share by Application (2017-2022)

5.2 Global Anti-Venom Revenue Market Share by Application (2017-2022)

5.3 Global Anti-Venom Price by Application (2017-2022)

6 Key Companies Profiled

6.1 CSL

6.1.1 CSL Corporation Information

6.1.2 CSL Description and Business Overview

6.1.3 CSL Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.1.4 CSL Anti-Venom Product Portfolio

6.1.5 CSL Recent Developments/Updates

6.2 Merck

6.2.1 Merck Corporation Information

6.2.2 Merck Description and Business Overview

6.2.3 Merck Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.2.4 Merck Anti-Venom Product Portfolio

6.2.5 Merck Recent Developments/Updates

6.3 BTG

6.3.1 BTG Corporation Information

6.3.2 BTG Description and Business Overview

6.3.3 BTG Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.3.4 BTG Anti-Venom Product Portfolio

6.3.5 BTG Recent Developments/Updates

6.4 Pfizer

6.4.1 Pfizer Corporation Information

6.4.2 Pfizer Description and Business Overview

6.4.3 Pfizer Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Pfizer Anti-Venom Product Portfolio

6.4.5 Pfizer Recent Developments/Updates

6.5 Haffkine Bio-Pharmaceutical

6.5.1 Haffkine Bio-Pharmaceutical Corporation Information

6.5.2 Haffkine Bio-Pharmaceutical Description and Business Overview

6.5.3 Haffkine Bio-Pharmaceutical Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.5.4 Haffkine Bio-Pharmaceutical Anti-Venom Product Portfolio

6.5.5 Haffkine Bio-Pharmaceutical Recent Developments/Updates

6.6 Rare Disease Therapeutics

6.6.1 Rare Disease Therapeutics Corporation Information

6.6.2 Rare Disease Therapeutics Description and Business Overview

6.6.3 Rare Disease Therapeutics Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.6.4 Rare Disease Therapeutics Anti-Venom Product Portfolio

6.6.5 Rare Disease Therapeutics Recent Developments/Updates

6.7 Flynn Pharma

6.6.1 Flynn Pharma Corporation Information

6.6.2 Flynn Pharma Description and Business Overview

6.6.3 Flynn Pharma Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.4.4 Flynn Pharma Anti-Venom Product Portfolio

6.7.5 Flynn Pharma Recent Developments/Updates

6.8 Vins Bioproducts

6.8.1 Vins Bioproducts Corporation Information

6.8.2 Vins Bioproducts Description and Business Overview

6.8.3 Vins Bioproducts Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.8.4 Vins Bioproducts Anti-Venom Product Portfolio

6.8.5 Vins Bioproducts Recent Developments/Updates

6.9 Bharat Serums and Vaccines

6.9.1 Bharat Serums and Vaccines Corporation Information

6.9.2 Bharat Serums and Vaccines Description and Business Overview

6.9.3 Bharat Serums and Vaccines Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.9.4 Bharat Serums and Vaccines Anti-Venom Product Portfolio

6.9.5 Bharat Serums and Vaccines Recent Developments/Updates

6.10 Serum Biotech

6.10.1 Serum Biotech Corporation Information

6.10.2 Serum Biotech Description and Business Overview

6.10.3 Serum Biotech Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.10.4 Serum Biotech Anti-Venom Product Portfolio

6.10.5 Serum Biotech Recent Developments/Updates

6.11 MicroPharm

6.11.1 MicroPharm Corporation Information

6.11.2 MicroPharm Anti-Venom Description and Business Overview

6.11.3 MicroPharm Anti-Venom Sales, Revenue and Gross Margin (2017-2022)

6.11.4 MicroPharm Anti-Venom Product Portfolio

6.11.5 MicroPharm Recent Developments/Updates

7 Anti-Venom Manufacturing Cost Analysis

7.1 Anti-Venom Key Raw Materials Analysis

7.1.1 Key Raw Materials

7.1.2 Key Suppliers of Raw Materials

7.2 Proportion of Manufacturing Cost Structure

7.3 Manufacturing Process Analysis of Anti-Venom

7.4 Anti-Venom Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

8.1 Marketing Channel

8.2 Anti-Venom Distributors List

8.3 Anti-Venom Customers

9 Anti-Venom Market Dynamics

9.1 Anti-Venom Industry Trends

9.2 Anti-Venom Market Drivers

9.3 Anti-Venom Market Challenges

9.4 Anti-Venom Market Restraints

10 Global Market Forecast

10.1 Anti-Venom Market Estimates and Projections by Type

10.1.1 Global Forecasted Sales of Anti-Venom by Type (2023-2028)

10.1.2 Global Forecasted Revenue of Anti-Venom by Type (2023-2028)

10.2 Anti-Venom Market Estimates and Projections by Application

10.2.1 Global Forecasted Sales of Anti-Venom by Application (2023-2028)

10.2.2 Global Forecasted Revenue of Anti-Venom by Application (2023-2028)

10.3 Anti-Venom Market Estimates and Projections by Region

10.3.1 Global Forecasted Sales of Anti-Venom by Region (2023-2028)

10.3.2 Global Forecasted Revenue of Anti-Venom by Region (2023-2028)

11 Research Finding and Conclusion

12 Methodology and Data Source

12.1 Methodology/Research Approach

12.1.1 Research Programs/Design

12.1.2 Market Size Estimation

12.1.3 Market Breakdown and Data Triangulation

12.2 Data Source

12.2.1 Secondary Sources

12.2.2 Primary Sources

12.3 Author List

12.4 Disclaimer

Choose License Type

Checkout Inquiry Sample